纵向tau与代谢PET成像与新型脑脊液tau标志物的关系
所有脑脊液tau水平与基线[18F]FDG摄取呈负相关,但与基线[18F]THK5317摄取的关联随皮层低代谢程度变化;新型标志物(tau-368、tau N-Mid)比P-tau181p和T-tau更好地追踪纵向示踪剂摄取变化。
要点
- 所有脑脊液tau水平与基线[18F]FDG摄取呈负相关。
- 脑脊液tau与基线[18F]THK5317摄取的关联随皮层低代谢程度变化。
- tau-368和tau N-Mid比P-tau181p和T-tau更好地追踪纵向tau PET变化。
核心结论
- 神经退行性变可能调节脑脊液与PET tau生物标志物之间的关系。
- 与P-tau181p和T-tau相比,tau-368和tau N-Mid可能更好地反映tau病理和突触损伤。
研究设计与样本
- 脑脊液检测包括商业 assay 和新型 assay(tau N-Mid、tau-368)。
主要发现
- 所有形式的脑脊液tau水平与基线[18F]FDG摄取呈负相关。
- 脑脊液tau与基线[18F]THK5317摄取的关联随皮层低代谢程度([18F]FDG SUVR)变化。
- 新型脑脊液标志物水平的变化比P-tau181p和T-tau水平的变化更好地追踪纵向示踪剂摄取变化。
- 新型标志物改善了与二分类区域[18F]THK5317测量的一致性。
临床怎么用
- 在AD中,解读脑脊液tau与tau PET的关联时需考虑神经退行性变(低代谢)程度。
- tau-368和tau N-Mid可能作为补充标志物,用于追踪tau病理和突触损伤的纵向变化。
局限性
- 随访时间仅17个月。
- 未报告诊断准确性或临床效用数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau181p) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both commercial and novel assays, in relation to [18F]THK5317 (tau) and [18F]FDG PET (glucose metabolism). METHODS: Fourteen Alzheimer's disease (AD) patients (seven prodromal, seven dementia) underwent [18F]THK5317 and [18F]FDG PET studies, with follow-up performed in ten subjects (six prodromal, four dementia) after 17 months. In addition to commercial assays, novel measures capturing N-terminus+mid-domain (tau N-Mid) and C-terminally truncated (tau-368) fragments were included. RESULTS: While the levels of all forms of CSF tau were found to be inversely associated with baseline [18F]FDG uptake, associations with baseline [18F]THK5317 uptake varied in relation to the degree of isocortical hypometabolism ([18F]FDG SUVR). Changes in the levels of the novel CSF markers tracked longitudinal changes in tracer uptake better than changes in P-tau181p and T-tau levels, and improved concordance with dichotomized regional [18F]THK5317 measures. CONCLUSION: Our findings suggest that neurodegeneration may modulate the relationship between CSF and PET tau biomarkers, and that, by comparison to P-tau181p and T-tau, tau-368 and tau N-Mid may better capture tau pathology and synaptic impairment.
引用
- Leuzy A, Cicognola C, Chiotis K, et al. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2019. PMID: 30610252. doi:10.1007/s00259-018-4242-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。